Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
12:01pm, Friday, 31'st Jul 2026
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street es
Organon (OGN) Lags Q2 Earnings Estimates
10:46am, Friday, 31'st Jul 2026
Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
Organon Announces Quarterly Dividend
08:30am, Friday, 31'st Jul 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 28'th Jul 2026
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Orogen Royalties Announces Project, Partner and Royalty Update
07:30am, Monday, 27'th Jul 2026
VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage proj
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
11:07am, Thursday, 23'rd Jul 2026
Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminar
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
07:30am, Thursday, 16'th Jul 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 15'th Jul 2026
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Orogen Royalties Begins Trading on OTCQX Best Market
08:00am, Friday, 10'th Jul 2026
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Orogen Royalties Inc. (TSXV:OGN)(OTCQX:OGNNF) ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on th
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:01am, Friday, 03'rd Jul 2026
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?
02:00pm, Thursday, 25'th Jun 2026
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
03:00pm, Wednesday, 24'th Jun 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
02:28pm, Wednesday, 24'th Jun 2026
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.
